Unique ID issued by UMIN | UMIN000020732 |
---|---|
Receipt number | R000022198 |
Scientific Title | An exploratory clinical trial for the congenital melanocytic nevi using the noble combination therapy with the inactivated autologous nevus tissue by high hydrostatic pressure and the cultured epithelial autograft |
Date of disclosure of the study information | 2016/01/26 |
Last modified on | 2019/01/26 15:46:19 |
An exploratory clinical trial for the congenital melanocytic nevi using the noble combination therapy with the inactivated autologous nevus tissue by high hydrostatic pressure and the cultured epithelial autograft
The noble combination therapy with the inactivated nevus tissue by high hydrostatic pressure and the cultured epithelial autograft
An exploratory clinical trial for the congenital melanocytic nevi using the noble combination therapy with the inactivated autologous nevus tissue by high hydrostatic pressure and the cultured epithelial autograft
The noble combination therapy with the inactivated nevus tissue by high hydrostatic pressure and the cultured epithelial autograft
Japan |
Melanocytic nevi
Plastic surgery |
Others
NO
Exploration of the take of the pressurized nevus in comnination with the cultured epidermal autograft
Safety,Efficacy
Exploratory
Explanatory
Phase I,II
The take of inactivated nevus with cultured epidermal autograft at 8weeks after implantation
Adverse events
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Device,equipment |
Apply cultured epidermal autografts on the pressirized nevusApply on the wound after the removal of the nevus
7 | months-old | <= |
Not applicable |
Male and Female
1.Patients with congenital pigmented nevus that can not be excised and sutured primarily
2.The area of the nevus is more than 0.25% of the body surface area
3.Operable patients more than 7 months old and
4.Written informed consent
1.Patients with scar tissue that prevent the take of inactivated nevus
2.The nevus that has been treated by cultured epidermal autografts already.
3.A history of malignant tumor with disease free interval of 5 years or less
4.Other patients judged by the
investigator or sub-investigator to be inappropriate as a subject of this study.
5.Patients who have received this protocol treatments twice.
10
1st name | |
Middle name | |
Last name | Naoki Morimoto |
Kansai Medical University
Department of Plastic and Reconstructive Surgery
2-5-1 Shin-machi, Hirakata City, Osaka
072-804-0101
morimotn@hirakata.kmu.ac.jp
1st name | |
Middle name | |
Last name | Omura Miyuki |
Kansai Medical University
Center for Clinical Research
2-5-1 Shin-machi, Hirakata City, Osaka
072-804-0101
http://www5.kmu.ac.jp/prs/index.html
kmuccr@hirakata.kmu.ac.jp
Department of Plastic and Reconstructive Surgery, Kansai Medical University
Japan Agency for Medical Research and Development
Japan
NO
関西医科大学附属枚方病院
2016 | Year | 01 | Month | 26 | Day |
Unpublished
Completed
2016 | Year | 01 | Month | 22 | Day |
2016 | Year | 02 | Month | 15 | Day |
2018 | Year | 08 | Month | 30 | Day |
2019 | Year | 03 | Month | 31 | Day |
2019 | Year | 04 | Month | 30 | Day |
2019 | Year | 06 | Month | 30 | Day |
2016 | Year | 01 | Month | 25 | Day |
2019 | Year | 01 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022198